Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitors
US-9340545-B2 · May 17, 2016 · US
Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors
US10028959B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10028959-B2 |
| Application number | US-201715474059-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 30, 2017 |
| Priority date | Oct 18, 2010 |
| Publication date | Jul 24, 2018 |
| Grant date | Jul 24, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
First claim
Opening claim text (preview).
The invention claimed is: 1. A dry powder pharmaceutical formulation for inhalation comprising: a compound of formula (I) that is 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. 2. A dry powder pharmaceutical formulation according to claim 1 , wherein the compound of formula (I) is in finely divided form. 3. A dry powder pharmaceutical formulation according to claim 2 , wherein the compound of formula (I) has a mass median diameter (MMAD) of 1-10 μm. 4. A dry powder pharmaceutical formulation according to claim 1 , wherein the compound of formula (I) is micronized. 5. A dry powder pharmaceutical formulation according to claim 1 , wherein the compound of formula (I) is in free base form.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
specific for metastasis · CPC title
Antineoplastic agents · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10028959B2 cover?
- The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
- Who is the assignee on this patent?
- Respivert Ltd, Respivert Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).